表紙
市場調查報告書
商品編碼
1035795

新興眼科給藥裝置市場:關注植入物、插入物和採樣塞——按給藥裝置類型和目標適應症(青光眼、視網膜靜脈阻塞、術後眼部炎症、非感染性葡萄膜炎)的分佈趨勢

Novel Ocular Drug Delivery Devices Market: Focus on Implants, Inserts and Punctal Plugs - Distribution by Type of Drug Delivery Device, Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis,

出版日期: | 出版商: Roots Analysis | 英文 201 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

參考圖片

概述

據美國疾病控制與預防中心 (CDC) 稱,視力不佳是一項超過 350 億美元的經濟負擔,包括生產力下降以及治療和長期護理的直接成本。對治療眼病以防止視力喪失的有效干預措施的需求不斷增長。傳統上,手術、激光和藥物干預(如血管生成抑製劑)已被用於治療眼病。但是,這些治療包括眼內註射和傳統手術的副作用,藥物在靶組織部位的生物利用度低,以及需要頻繁給藥才能長期保持療效等都是有限度的。此外,目前市場上90%以上的眼科製劑以滴眼液的形式提供,主要用於與眼前節相關的疾病。研究表明,當與外用眼藥水一起給藥時,由於淚液稀釋和角膜滲透問題等諸多挑戰,大約 95% 的藥物會丟失。因此,眼藥水和藥膏等藥物並不是治療威脅視力的疾病的最佳方法。

在此背景下,對能夠克服生物利用度問題並在適當的時間段內以有效濃度將藥物遞送至靶細胞的有效、非侵入性藥物遞送系統的需求不斷增加。迄今為止,全球多家製藥公司已經開發出緩釋植入物、眼部插入物和穿刺塞等新型給藥裝置,在克服現有挑戰的同時實現有效給藥,我們為此做出了各種努力。事實上,在過去的幾年裡,新興的眼科給藥裝置已經申請並獲得了1100多項專利,並且還在不斷創新。隨著患者人數的增加以及新型和先進的眼科給藥裝置的推出,新興的眼科給藥裝置市場有望在未來幾年穩步增長。

本報告探討了新興的眼科給藥設備市場、市場概況、細分分析、類型案例研究、臨床試驗分析、合作夥伴合作趨勢、資金和投資分析、專利分析,總結了市場規模/機會分析、主要公司概況、等等。

目錄

第一章前言

第 2 章執行摘要

第 3 章介紹

  • 章節概述
  • 眼睛結構
  • 眼科給藥途徑
  • 眼科給藥系統
    • 樹枝狀聚合物
    • 水凝膠
    • 脂質體
    • 納米膠卷
    • 納米粒子
  • 一般說明

第 4 章市場概覽

  • 章節概述
  • 新興眼科給藥裝置:整體市場情況
    • 按給藥裝置類型分析
    • 按當前開發狀態
    • 給藥裝置類型及發展現狀分析
    • 按產品類型分析
    • 按給藥裝置類型/產品類型進行分析
    • 按分子類型分析
    • 按目標指示分析
    • 按給藥途徑分析
  • 新興眼科給藥裝置:開發者現狀
    • 按成立年份分析
    • 公司規模分析
    • 按總部所在地分析
    • 行業主要公司分析:按設備數量

第 5 章案例研究:新興眼科給藥裝置的類型

  • 章節概述
  • 新興的眼科給藥裝置
    • 仿生眼
    • 人工晶狀體
    • 滴眼液分配裝置
  • 其他

第六章公司簡介

  • 章節概述
  • Alimera 科學
    • 公司簡介
    • 技術概述
    • 產品組合
    • 近期趨勢和未來前景
  • 博士倫
  • EyePoint 製藥
  • 基因泰克
  • 格勞科斯
  • 神經科技製藥
  • 眼部治療

第七章臨床試驗分析

  • 章節概述
  • 範圍和研究方法
  • 新興眼科給藥裝置:臨床試驗分析
    • 按註冊年份分析
    • 臨床試驗階段分析
    • 按學科招募狀況分析
    • 按註冊患者人群和發展階段分析
    • 調查設計分析
    • 按目標患者細分的分析
    • 按目標指示分析
    • 按贊助商屬性分析
    • 最活躍公司分析:按註冊臨床試驗數量分析
    • 按地區劃分的註冊臨床試驗/分析數量

第8章夥伴協作

  • 章節概述
  • 合作模式
  • 新興眼科給藥裝置:合作夥伴關係
    • 按合作年份分析
    • 合作類型分析
    • 按合作年份和類型進行分析
    • 最活躍公司的分析:按合作夥伴數量
    • 區域分析

第9章融資/投資分析

  • 章節概述
  • 資金類型
  • 新興眼科給藥設備市場:融資/投資分析
    • 按投資年度分析
    • 按投資金額分析
    • 按融資類型分析
    • 資金類型投資金額分析
    • 按融資數量分析最活躍的公司
    • 區域分析

第10章專利分析

  • 章節概述
  • 範圍和研究方法
  • 新興眼科給藥裝置:專利分析
    • 按發行年份分析
    • 區域分析
    • 按每次點擊費用符號分析
    • 新的優先領域
    • 按給藥裝置類型分析
    • 按學科類型分析
    • 主要公司分析:按患者人數
  • 新興眼科給藥裝置:專利基準分析
    • 按專利特徵分析
  • 新興眼科給藥裝置:專利評價分析
  • 主要專利:按引用次數分析

第11章市場規模/機會分析

  • 章節概述
  • 預測性研究方法/主要假設
  • 全球新興眼科給藥裝置市場(2021-2030)
    • 按給藥裝置類型劃分的分配量
    • 按目標指示分配的金額
    • 按產品類型分配的數量
    • 按地區分配數量

第12章結論

第 13 章高管洞察力

第14章附錄1:匯總數據

第 15 章附錄 2:公司/組織名單

目錄

Title:
Novel Ocular Drug Delivery Devices Market:
Focus on Implants, Inserts and Punctal Plugs - Distribution by Type of Drug Delivery Device, Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet AMD and Others), Type of Product (Biodegradable and Non-Biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2021-2030.

VISUALS

Overview:

According to the World Health Organization (WHO), more than 2.2 billion individuals across the world suffer from some degree of vision impairment caused due to various ophthalmic disorders, such as glaucoma, trachoma, cataract, diabetic retinopathy and wet age-related macular degeneration. Around 50% of the cases are left either unaddressed and / or could have been prevented. It is also worth highlighting that around 1.7 billion individuals worldwide are expected to lose their vision by 2050. As per the Centers for Disease Control and Prevention (CDC), loss of vision can pose an economic burden of over USD 35 billion, in terms of loss of productivity and direct costs of treatment / care. Considering the aforementioned facts, there is a rise in demand for effective therapeutic interventions for the treatment of ocular diseases, in order to prevent complete vision loss. Conventionally, ocular diseases have been treated through surgery, laser or pharmacological interventions (such as anti-angiogenic drugs). However, these treatment options are associated with several limitations, including side effects of intravitreal injections and conventional surgeries, poor drug bioavailability at the target tissue site and need for frequent drug administration to maintain efficacy for a longer duration. In addition, at present, more than 90% of the marketed ophthalmic formulations are available in the form of eye drops that mainly target diseases related to anterior segment of the eye. Studies suggest that, if administered with the help of topical eye drops, around 95% of the drug is lost due to a number of challenges, such as dilution of product by tears and permeation issues related to cornea. Therefore, drug delivery formulations, such as eye drops and ointments, cannot be considered as an optimal treatment option for vision-threatening diseases.

Owing to the aforementioned concerns, there is an evident rise in the demand for effective, non-invasive drug delivery systems that are capable of overcoming bioavailability hurdles and enable delivery of the drug at the target cells, at effective concentrations, for a suitable period of time. Over time, several pharmaceutical companies across the world have undertaken various initiatives to develop novel drug delivery devices, such as sustained release implants, ocular inserts and punctal plugs, that are capable of enabling effective administration of drugs, while overcoming the existing challenges. In fact, over 1,100 patents related to novel ocular drug delivery devices have been filed / granted in the past few years, demonstrating the continued innovation being carried out in this domain. The growing interest of pharmaceutical stakeholders in this field is also reflected from the recent rise in partnership activity of novel ocular drug delivery device developers. Driven by the increasing patient population and introduction of novel and advanced ocular drug delivery devices, this market is anticipated to witness steady growth in the coming years.

Scope of the Report:

The "Novel Ocular Drug Delivery Devices Market by Type of Drug Delivery Device (Implants, Inserts and Punctal Plugs), Target Indications (Glaucoma, Retinal Vein Occlusion, Postoperative Ocular Inflammation, Non-Infectious Uveitis, Diabetic Macular Edema, Dry Eye Disease, Wet Age-related Macular Degeneration, Retinal Diseases, Neovascular Age-Related Macular Degeneration and Others), Type of Product (Biodegradable and Non-biodegradable) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2030" report features an extensive study of the current market landscape and the likely adoption of novel ocular drug delivery devices, over the next decade. The study features a detailed analysis of the key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of novel ocular drug delivery devices, with respect to type of drug delivery device (implants, inserts and punctal plugs) , current status of development (marketed, phase III, phase II, phase I / II, phase I and preclinical) , type of product (biodegradable and non-biodegradable) , type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).
  • Elaborate profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), information on technology use, respective product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.
  • An analysis of the partnerships that have been established in this domain during the period 2012-2021 covering R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and other related agreements.
  • An analysis of the investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.
  • An in-depth analysis of over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted) , patent benchmarking and valuation.
  • A case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers and others.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for novel ocular drug delivery devices over the coming decade. Additionally, it features market size projections for the overall novel ocular drug delivery devices market, wherein both the current and upcoming opportunity is segmented across [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indications (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) , [C] type of product (biodegradable and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry's evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Eyal Sheetrit (Chief Executive Officer and President, Eximore)
  • Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea)

Key Questions Answered:

  • Who are the leading novel ocular drug delivery device developers?
  • Which are the popular types of novel ocular drug delivery devices available in this market?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • What types of partnership models are commonly being adopted by stakeholders in this industry?
  • Who are the key investors in this domain?
  • How is the intellectual property landscape in this field likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the novel ocular drug delivery devices market in the short to mid-term and long term.

Chapter 3 provides a general overview of the structure of eye and its associated routes of drug administration. Additionally, it provides information on the popular ocular drug delivery systems (dendrimers, hydrogels, liposomes, nanomicelles and nanoparticles) .

Chapter 4 includes detailed assessment on novel ocular drug delivery devices that are currently approved or are in different stages of development. It features a comprehensive analysis of novel ocular drug delivery devices with respect to type of drug delivery device (implants, inserts and punctal plugs), current status of development (marketed, phase III, phase II, phase I/II, phase I and preclinical) , type of product (biodegradable and non-biodegradable), type of molecule (small molecules and biologics), target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) and route of administration (topical, intravitreal, intracameral, intracanalicular, implantable and subconjunctival). In addition, the chapter lists novel ocular drug delivery device developers, along with information on their respective year of establishment, company size, location of headquarters and most active players (in terms of number of devices).

Chapter 5 provides detailed case study on the available novel ocular drug delivery devices such as bionic eye, intraocular lenses, eye-drop dispensers, and others.

Chapter 6 includes detailed profiles of key players that are engaged in the development of novel ocular drug delivery devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives) , information on technology use, respective product portfolio, recent developments and an informed future outlook.

Chapter 7 presents an in-depth analysis of completed, ongoing and planned clinical studies of various novel ocular drug delivery devices based on relevant parameters, such as trial registration year, trial recruitment status, phase of development, study design, target patient segment, target indication, type of sponsor, most active players (in terms of number of registered trials conducted) and key geographical regions.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, during the period 2012-2021 . Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership model (R&D agreements, product commercialization agreements, product development and commercialization agreements, product distribution agreements, technology licensing agreements, product development agreements, acquisitions, product licensing agreements and others) , and regional distribution of the collaborations.

Chapter 9 provides details on the various investments that have been made into companies with proprietary novel ocular drug delivery devices, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing. The investment instances have been analyzed based on various relevant parameters, such as year of investment, amount invested, type of funding, most active players (in terms of number of funding instances) and type of investor.

Chapter 10 provides an in-depth over 1,100 patents filed / granted related to novel ocular drug delivery devices, till 2021. The instances have been analyzed based on various relevant parameters, such as type of patent, publication year, regional applicability, CPC symbols, emerging focus areas, type of drug delivery device, type of applicant, leading patent assignees (in terms of number of patents filed / granted) , patent benchmarking and valuation.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of novel till the year 2030. In order to provide details on the future opportunity, our projections have been segmented across important market segments, namely [A] type of drug delivery device (implants, inserts and punctal plugs), [B] target indication (glaucoma, retinal vein occlusion, postoperative ocular inflammation, non-infectious uveitis, diabetic macular edema, dry eye disease, wet age-related macular degeneration, retinal diseases, neovascular age-related macular degeneration and others) , [C] type of product (biodegradable and non-biodegradable) and [D] key geographies (North America, Europe, Asia Pacific and rest of the world) .

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with key stakeholders of this market. In this chapter, we have presented the details of our conversation with Eyal Sheetrit (Chief Executive Officer and President, Eximore) and Murty Vyakarnam (Chief Executive Officer and Co-founder, Oculinea).

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Structure of the Eye
  • 3.3. Routes for Ocular Drug Delivery
  • 3.4. Ocular Drug Delivery Systems
    • 3.4.1. Dendrimers
    • 3.4.2. Hydrogels
    • 3.4.3. Liposomes
    • 3.4.4. Nanomicelles
    • 3.4.5. Nanoparticles
  • 3.5. Concluding Remarks

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Novel Ocular Drug Delivery Devices: Overall Market Landscape
    • 4.2.1. Analysis by Type of Drug Delivery Device
    • 4.2.2. Analysis by Current Status of Development
    • 4.2.3. Analysis by Type of Drug Delivery Device and Current Status of Development
    • 4.2.4. Analysis by Type of Product
    • 4.2.5. Analysis by Type of Drug Delivery Device and Type of Product
    • 4.2.6. Analysis by Type of Molecule
    • 4.2.7. Analysis by Target Indication
    • 4.2.8. Analysis by Route of Administration
  • 4.3. Novel Ocular Drug Delivery Devices: Developer Landscape
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Key Industry Players: Analysis by Number of Devices

5. CASE STUDY: TYPES OF NOVEL OCULAR DRUG DELIVERY DEVICES

  • 5.1. Chapter Overview
  • 5.2. Novel Ocular Drug Delivery Devices
    • 5.2.1. Bionic Eye
      • 5.2.1.1. Working of a Bionic Eye
    • 5.2.2. Intra Ocular Lenses
      • 5.2.2.1. Evolution of Intra Ocular Lenses
      • 5.2.2.2. Applications of Intra Ocular Lenses
      • 5.2.2.3. Types of Intra Ocular Lenses
      • 5.2.2.4. Classification of Intra Ocular Lenses
    • 5.2.3. Eye Drop Dispenser Devices
  • 5.3. Other Novel Ocular Drug Delivery Systems

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. Alimera Sciences
    • 6.2.1. Company Overview
    • 6.2.2. Technology Overview
    • 6.2.3. Product Portfolio
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Bausch and Lomb
    • 6.3.1. Company Overview
    • 6.3.2. Technology Overview
    • 6.3.3. Product Portfolio
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. EyePoint Pharmaceuticals
    • 6.4.1. Company Overview
    • 6.4.2. Technology Overview
    • 6.4.3. Product Portfolio
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Genentech
    • 6.5.1. Company Overview
    • 6.5.2. Technology Overview
    • 6.5.3. Product Portfolio
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Glaukos
    • 6.6.1. Company Overview
    • 6.6.2. Technology Overview
    • 6.6.3. Product Portfolio
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Neurotech Pharmaceuticals
    • 6.7.1. Company Overview
    • 6.7.2. Technology Overview
    • 6.7.3. Product Portfolio
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Ocular Therapeutix
    • 6.8.1. Company Overview
    • 6.8.2. Technology Overview
    • 6.8.3. Product Portfolio
    • 6.8.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Novel Ocular Drug Delivery Devices: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2 Analysis by Trial Phase
    • 7.3.3. Analysis by Trial Recruitment Status
    • 7.3.4. Analysis by Trial Registration Year and Enrolled Patient Population
    • 7.3.5. Analysis by Enrolled Patient Population and Phase of Development
    • 7.3.6. Analysis by Study Design
    • 7.3.7. Analysis by Target Patient Segment
    • 7.3.8. Analysis by Target Indication
    • 7.3.9. Analysis by Type of Sponsor
    • 7.3.10. Most Active Players: Analysis by Number of Registered Trials
    • 7.3.11. Analysis by Number of Registered Trials and Geography

8. PARTNERSHIPS AND COLLABORATIONS

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Novel Ocular Drug Delivery Devices: Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Most Active Players: Analysis by Number of Partnerships
    • 8.3.5. Analysis by Geography
      • 8.3.5.1. Region-wise Distribution
      • 8.3.5.2. Country-wise Distribution

9. FUNDING AND INVESTMENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Type of Funding
  • 9.3. Novel Ocular Drug Delivery Devices Market: Funding and Investment Analysis
    • 9.3.1. Analysis by Year of Investment
    • 9.3.2. Analysis by Amount Invested
    • 9.3.3. Analysis by Type of Funding
    • 9.3.4. Analysis of Amount Invested by Type of Funding
    • 9.3.5. Most Active Players: Analysis by Number of Funding Instances
    • 9.3.6. Analysis by Type of Investor
    • 9.3.7. Most Active Investors: Analysis by Number of Funding Instances
    • 9.3.8. Analysis by Geography

10. PATENT ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Novel Ocular Drug Delivery Devices: Patent Analysis
    • 10.3.1. Analysis by Publication Year
    • 10.3.2. Analysis by Geography
    • 10.3.3. Analysis by CPC Symbols
    • 10.3.4 Emerging Focus Areas
    • 10.3.5. Analysis by Type of Drug Delivery Device
    • 10.3.6. Analysis by Type of Applicant
    • 10.3.7. Leading Players: Analysis by Number of Patents
  • 10.4. Novel Ocular Drug Delivery Devices: Patent Benchmarking Analysis
    • 10.4.1 Analysis by Patent Characteristics
  • 10.5. Novel Ocular Drug Delivery Devices: Patent Valuation Analysis
  • 10.6. Leading Patents: Analysis by Number of Citations

11. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology and Key Assumptions
  • 11.3. Global Novel Ocular Drug Delivery Devices Market, 2021-2030
    • 11.3.1. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Drug Delivery Device
      • 11.3.1.1. Novel Ocular Drug Delivery Devices Market for Implants, 2021-2030
      • 11.3.1.2. Novel Ocular Drug Delivery Devices Market for Inserts, 2021-2030
      • 11.3.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs, 2021-2030
    • 11.3.2. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Target Indication
    • 11.3.3. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Type of Product
    • 11.3.4. Novel Ocular Drug Delivery Devices Market, 2021-2030: Distribution by Geography
      • 11.3.4.1. Novel Ocular Drug Delivery Devices Market in North America, 2021-2030
        • 11.3.4.1.1. Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030
        • 11.3.4.1.2. Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030
        • 11.3.4.1.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030
      • 11.3.4.2. Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030
        • 11.3.4.2.1. Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030
        • 11.3.4.2.2. Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030
        • 11.3.4.2.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030
      • 11.3.4.3. Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030
        • 11.3.4.3.1. Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030
        • 11.3.4.3.2. Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030
        • 11.3.4.3.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030
      • 11.3.4.4. Novel Ocular Drug Delivery Devices Market Rest of the World, 2021-2030
        • 11.3.4.4.1. Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030
        • 11.3.4.4.2. Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030
        • 11.3.4.4.3. Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. Eximore
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: Eyal Sheetrit, Co-Founder and Chief Executive Officer
  • 13.3. Oculinea
    • 13.3.1. Company Snapshot
    • 13.3.2. Interview Transcript: Murty Vyakarnam, Co-Founder and Chief Executive
  • Officer

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 2.1 Executive Summary: Overview of Market Landscape and Developer Landscape
  • Figure 2.2 Executive Summary: Clinical Trial Activity and Partnership Activity
  • Figure 2.3 Executive Summary: Funding and Investment Analysis and Patent Analysis
  • Figure 2.4 Executive Summary: Market Forecast
  • Figure 3.1 Structure of the Eye
  • Figure 3.2 Layers of Tissues in the Eye
  • Figure 3.3 Types of Ocular Drug Delivery Systems
  • Figure 3.4 Marketed Ocular Drug Delivery Implants
  • Figure 4.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
  • Figure 4.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
  • Figure 4.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
  • Figure 4.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
  • Figure 4.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
  • Figure 4.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
  • Figure 4.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
  • Figure 4.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
  • Figure 4.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
  • Figure 4.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
  • Figure 4.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
  • Figure 4.12 Key Industry Players: Distribution by Number of Devices
  • Figure 5.1 Bionic Eye: External and Implantable Modules
  • Figure 5.2 Visual Prosthesis: Mode of Operation
  • Figure 5.3 Evolution of Intraocular Lenses
  • Figure 5.4 Applications of Bandage Intraocular Lenses
  • Figure 7.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
  • Figure 7.2 Clinical Trial Analysis: Distribution by Phase of Development
  • Figure 7.3 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011 - 2021
  • Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
  • Figure 7.6 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
  • Figure 7.7 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.8 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 7.9 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 7.10 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 7.11 Most Active Players: Distribution by Number of Registered Trials
  • Figure 7.12 Clinical Trial Analysis: Distribution by Geography
  • Figure 8.1 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 8.4 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.5 Partnerships and Collaborations: Distribution by Region
  • Figure 8.6 Partnerships and Collaborations: Distribution by Country
  • Figure 9.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
  • Figure 9.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year (USD Million)
  • Figure 9.3 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 9.4 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
  • Figure 9.5 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding (USD Million)
  • Figure 9.6 Most Active Players: Distribution by Number of Funding Instances
  • Figure 9.7 Funding and Investment Analysis: Distribution by Type of Investor
  • Figure 9.8 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 9.9 Funding and Investment Analysis: Distribution by Geography
  • Figure 10.1 Patent Analysis: Distribution by Patent Filed
  • Figure 10.2 Patent Analysis: Distribution by Year of Publication, 2002-2021
  • Figure 10.3 Patent Analysis: Distribution by Location of Patent Jurisdiction
  • Figure 10.4 Patent Analysis: Distribution by Jurisdiction
  • Figure 10.5 Patent Analysis: Distribution by CPC Symbols
  • Figure 10.6 Patent Analysis: Emerging Focus Areas
  • Figure 10.7 Patent Analysis: Distribution by Type of Drug Delivery Device
  • Figure 10.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 10.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 10.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 10.11 Leading Patent Assignees: Distribution by Number of Patents
  • Figure 10.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
  • Figure 10.13 Patent Analysis: Distribution by Patent Age
  • Figure 10.14 Novel Ocular Drug Delivery Devices: Patent Valuation
  • Figure 11.1 Global Novel Ocular Drug Delivery Devices Market, 2021-2030 (USD Million)
  • Figure 11.2 Novel Ocular Drug Delivery Market for Implants, 2021-2030 (USD Million)
  • Figure 11.3 Novel Ocular Drug Delivery Market for Inserts, 2021-2030 (USD Million)
  • Figure 11.4 Novel Ocular Drug Delivery Market for Punctal Plugs, 2021-2030 (USD Million)
  • Figure 11.5 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
  • Figure 11.6 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
  • Figure 11.7 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
  • Figure 11.8 Novel Ocular Drug Delivery Devices Market in North America, 2021-2030 (USD Million)
  • Figure 11.9 Novel Ocular Drug Delivery Devices Market for Implants in North America, 2021-2030 (USD Million)
  • Figure 11.10 Novel Ocular Drug Delivery Devices Market for Inserts in North America, 2021-2030 (USD Million)
  • Figure 11.11 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, 2021-2030 (USD Million)
  • Figure 11.12 Novel Ocular Drug Delivery Devices Market in Europe, 2021-2030 (USD Million)
  • Figure 11.13 Novel Ocular Drug Delivery Devices Market for Implants in Europe, 2021-2030 (USD Million)
  • Figure 11.14 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, 2021-2030 (USD Million)
  • Figure 11.15 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, 2021-2030 (USD Million)
  • Figure 11.16 Novel Ocular Drug Delivery Devices Market in Asia Pacific, 2021-2030 (USD Million)
  • Figure 11.17 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, 2021-2030 (USD Million)
  • Figure 11.18 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, 2021-2030 (USD Million)
  • Figure 11.19 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, 2021-2030 (USD Million)
  • Figure 11.20 Novel Ocular Drug Delivery Devices Market in Rest of the World, 2021-2030 (USD Million)
  • Figure 11.21 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, 2021-2030 (USD Million)
  • Figure 11.22 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, 2021-2030 (USD Million)
  • Figure 11.23 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, 2021-2030 (USD Million)
  • Figure 12.1 Concluding Remarks: Overall Market Landscape
  • Figure 12.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 12.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 12.4 Concluding Remarks: Funding and Investment Analysis
  • Figure 12.5 Concluding Remarks: Market Forecast

List Of Tables

  • Table 3.1 Routes for Ocular Drug Delivery
  • Table 4.1 Novel Ocular Drug Delivery: Overall Market Landscape
  • Table 4.2 Novel Ocular Drug Delivery Devices: List of Developers
  • Table 5.1 Bionic Eye Systems: Information on Device Developer, Headquarters, Target Indication and Site of Implant Placement
  • Table 5.2 Advantages and Disadvantages of Different Types of Intraocular Lenses
  • Table 5.3 Therapeutic Intraocular Lenses: Information on Developer, Headquarters, Target Indication and Type of product
  • Table 5.4 Eye-Drop Dispenser Devices: Information on Developer, Headquarters and Target Site
  • Table 5.5 Other Novel Ocular Drug Delivery Devices: Information on Technology, Type of Product, Developer, Year of Establishment, Company Size and Headquarters
  • Table 6.1 List of Companies Profiled
  • Table 6.2 Alimera Sciences: Company Overview
  • Table 6.3 Alimera Sciences: Technology Overview
  • Table 6.4 Alimera Sciences: Product Portfolio
  • Table 6.5 Alimera Sciences: Recent Developments and Future Outlook
  • Table 6.6 Bausch and Lomb: Company Overview
  • Table 6.7 Bausch and Lomb: Technology Overview
  • Table 6.8 Bausch and Lomb: Product Portfolio
  • Table 6.9 Bausch and Lomb: Recent Developments and Future Outlook
  • Table 6.10 EyePoint Pharmaceuticals: Company Overview
  • Table 6.11 EyePoint Pharmaceuticals: Technology Overview
  • Table 6.12 EyePoint Pharmaceuticals: Product Portfolio
  • Table 6.13 EyePoint Pharmaceuticals: Recent Developments and Future Outlook
  • Table 6.14 Genentech: Company Overview
  • Table 6.15 Genentech: Technology Overview
  • Table 6.16 Genentech: Product Portfolio
  • Table 6.17 Glaukos: Company Overview
  • Table 6.18 Glaukos: Technology Overview
  • Table 6.19 Glaukos: Product Portfolio
  • Table 6.20 Glaukos: Recent Developments and Future Outlook
  • Table 6.21 Neurotech Pharmaceuticals: Company Overview
  • Table 6.22 Neurotech Pharmaceuticals: Technology Overview
  • Table 6.23 Neurotech Pharmaceuticals: Product Portfolio
  • Table 6.24 Ocular Therapeutix: Company Overview
  • Table 6.25 Ocular Therapeutix: Technology Overview
  • Table 6.26 Ocular Therapeutix: Product Portfolio
  • Table 6.27 Ocular Therapeutix: Recent Developments and Future Outlook
  • Table 7.1 Novel Ocular Drug Delivery Devices: List of Clinical Trials
  • Table 8.1 Novel Ocular Drug Delivery Devices: List of Partnerships and Collaborations, 2012-2021
  • Table 9.1 Novel Ocular Drug Delivery Devices: Funding and Investments, Pre-2011-2021
  • Table 9.2 Novel Ocular Drug Delivery Devices: Summary of Investments
  • Table 10.1 Patent Analysis: Prominent CPC Symbols
  • Table 10.2 Patent Analysis: Most Popular CPC Symbols
  • Table 10.3 Patent Analysis: List of Top CPC Symbols
  • Table 10.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 10.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 10.6 Patent Portfolio: List of Leading Patents (In terms of Highest Relative Valuation)
  • Table 10.7 Patent Portfolio: List of Leading Patents (In terms of Number of Citations)
  • Table 13.1 Eximore: Company Snapshot
  • Table 13.2 Oculinea: Company Snapshot
  • Table 14.1 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device
  • Table 14.2 Novel Ocular Drug Delivery Devices: Distribution by Current Status of Development
  • Table 14.3 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Current Status of Development
  • Table 14.4 Novel Ocular Drug Delivery Devices: Distribution by Type of Product
  • Table 14.5 Novel Ocular Drug Delivery Devices: Distribution by Type of Drug Delivery Device and Type of Product
  • Table 14.6 Novel Ocular Drug Delivery Devices: Distribution by Type of Molecule
  • Table 14.7 Novel Ocular Drug Delivery Devices: Distribution by Target Indication
  • Table 14.8 Novel Ocular Drug Delivery Devices: Distribution by Route of Administration
  • Table 14.9 Novel Ocular Drug Delivery Device Developers: Distribution by Year of Establishment
  • Table 14.10 Novel Ocular Drug Delivery Device Developers: Distribution by Company Size
  • Table 14.11 Novel Ocular Drug Delivery Device Developers: Distribution by Location of Headquarters
  • Table 14.12 Key Industry Players: Distribution by Number of Devices
  • Table 14.13 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2011-2021
  • Table 14.14 Clinical Trial Analysis: Distribution by Phase of Development
  • Table 14.15 Clinical Trial Analysis: Distribution by Trial Recruitment Status
  • Table 14.16 Clinical Trial Analysis: Distribution by Trial Registration Year and Recruitment Status, Pre-2011-2021
  • Table 14.17 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
  • Table 14.18 Clinical Trial Analysis: Distribution by Enrolled Patient Population and Phase of Development
  • Table 14.19 Clinical Trial Analysis: Distribution by Study Design
  • Table 14.20 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 14.21 Clinical Trial Analysis: Distribution by Target Indication
  • Table 14.22 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 14.23 Most Active Players: Distribution by Number of Registered Trials
  • Table 14.24 Clinical Trial Analysis: Distribution by Geography
  • Table 14.25 Partnerships and Collaborations: Cumulative Distribution by Year, 2012-2021
  • Table 14.26 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 14.27 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 14.28 Most Active Players: Distribution by Number of Partnerships
  • Table 14.29 Partnerships and Collaborations: Distribution by Region
  • Table 14.30 Partnerships and Collaborations: Distribution by Country
  • Table 14.31 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2011-2021
  • Table 14.32 Funding and Investment Analysis: Cumulative Distribution by Amount Invested and Year (USD Million)
  • Table 14.33 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 14.34 Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Funding (USD Million)
  • Table 14.35 Funding and Investment Analysis: Heat-map Representation of Amount Invested and Type of Funding, Pre-2011-2021(USD Million)
  • Table 14.36 Most Active Players: Distribution by Number of Funding Instances
  • Table 14.37 Funding and Investment Analysis: Distribution by Type of Investor
  • Table 14.38 Most Active Investors: Distribution by Number of Funding Instances
  • Table 14.39 Funding and Investment Analysis: Distribution by Geography
  • Table 14.40 Patent Analysis: Distribution by Type of Patent
  • Table 14.41 Patent Analysis: Distribution by Year of Publication, 2002-2021
  • Table 14.42 Patent Analysis: Distribution by Geography
  • Table 14.43 Patent Analysis: Distribution by Jurisdiction
  • Table 14.44 Patent Analysis: Distribution by CPC Symbols
  • Table 14.45 Patent Analysis: Distribution by Type of Drug Delivery Device
  • Table 14.46 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 14.47 Leading Industry Players: Distribution by Number of Patents
  • Table 14.48 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 14.49 Leading Patent Assignees: Distribution by Number of Patents
  • Table 14.50 Patent Analysis: Distribution by Patent Age
  • Table 14.51 Novel Ocular Drug Delivery Devices: Patent Valuation
  • Table 14.52 Global Novel Ocular Drug Delivery Devices Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.53 Novel Ocular Drug Delivery Market for Implants, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.54 Novel Ocular Drug Delivery Market for Inserts, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.55 Novel Ocular Drug Delivery Market for Punctal Plugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.56 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Target Indication (USD Million)
  • Table 14.57 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Type of Product (USD Million)
  • Table 14.58 Novel Ocular Drug Delivery Devices Market, 2021 and 2030: Distribution by Geography (USD Million)
  • Table 14.59 Novel Ocular Drug Delivery Devices Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.60 Novel Ocular Drug Delivery Devices Market for Implants in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.61 Novel Ocular Drug Delivery Devices Market for Inserts in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.62 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.63 Novel Ocular Drug Delivery Devices Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.64 Novel Ocular Drug Delivery Devices Market for Implants in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.65 Novel Ocular Drug Delivery Devices Market for Inserts in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.66 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.67 Novel Ocular Drug Delivery Devices Market in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.68 Novel Ocular Drug Delivery Devices Market for Implants in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.69 Novel Ocular Drug Delivery Devices Market for Inserts in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.70 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Asia Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.71 Novel Ocular Drug Delivery Devices Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.72 Novel Ocular Drug Delivery Devices Market for Implants in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.73 Novel Ocular Drug Delivery Devices Market for Inserts in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
  • Table 14.74 Novel Ocular Drug Delivery Devices Market for Punctal Plugs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. 20/20 OptimEyes Technologies
  • 2. 23andMe
  • 3. Aciont
  • 4. AcuFocus
  • 5. Adaptive Biotechnologies
  • 6. Aerie Pharmaceuticals
  • 7. Aero Pump
  • 8. AffaMed Therapeutics
  • 9. Akarna Therapeutics
  • 10. Alcon
  • 11. Alcon
  • 12. Alibaba Health Information Technology
  • 13. Alimera Sciences
  • 14. Allergan
  • 15. Alta Partners
  • 16. Amorphex Therapeutics
  • 17. Angiotech Pharmaceuticals
  • 18. Anthrogenesis
  • 19. Ascension Ventures
  • 20. Atalanta
  • 21. Avedro
  • 22. Avizorex Pharma
  • 23. Bausch & Lomb
  • 24. Brien Holden Vision Institute (BHVI)
  • 25. BioHealthWays
  • 26. Bionic Vision Technologies
  • 27. Brandon Capital partners
  • 28. BTG
  • 29. Burrill & Company
  • 30. Cella Therapeutics
  • 31. Children's National Hospital
  • 32. ChromaGen Vision
  • 33. Cirle
  • 34. Clarus Ventures
  • 35. Clearside Biomedical
  • 36. Corporate Renaissance Group
  • 37. D. Western Therapeutics Institute
  • 38. Deerfield
  • 39. DelSiTech
  • 40. Department of Defense
  • 41. Domain Associates
  • 42. DSM
  • 43. Envisia Therapeutics
  • 44. Escalon Medical
  • 45. EW Healthcare Partners
  • 46. Eximore
  • 47. EYE-GO
  • 48. EyePoint Pharmaceuticals
  • 49. Eyevensys
  • 50. FB VISION
  • 51. Fjord Ventures
  • 52. Foundry Therapeutics
  • 53. Frazier Healthcare Partners
  • 54. Genentech
  • 55. Genesis Therapeutics
  • 56. Glaukos
  • 57. Graybug Vision
  • 58. Gund Investment
  • 59. Gyroscope Therapeutics
  • 60. Heptares Therapeutics
  • 61. Horizon Discovery
  • 62. Horus Pharma
  • 63. IDVentures
  • 64. IDA Ireland
  • 65. Imbio
  • 66. ImprimisRx
  • 67. Incept
  • 68. InterWest Partners
  • 69. Intratus
  • 70. Invest Michigan
  • 71. IQVIA
  • 72. Johnson & Johnson Vision
  • 73. Kala Pharmaceuticals
  • 74. Kedalion Therapeutics
  • 75. Kineta
  • 76. Knight Therapeutics
  • 77. Kodiak Sciences
  • 78. Laboratoires Thea
  • 79. Laurus Labs
  • 80. LayerBio
  • 81. Lodo Therapeutics
  • 82. M25
  • 83. Mati Therapeutics
  • 84. MEAgate
  • 85. Medical Research Commercialisation Fund (MRCF)
  • 86. Medis
  • 87. Merck
  • 88. Mercury Fund
  • 89. Meritech Capital Partners
  • 90. Microchip Technology
  • 91. Micropore Technologies
  • 92. MilliporeSigma
  • 93. Modulight
  • 94. Monash Vision Group
  • 95. Montreaux Growth Partners
  • 96. MuPharma
  • 97. Mystic Pharmaceuticals
  • 98. Nanomerics
  • 99. Nanyang Technological University
  • 100. National Institutes of Health (NIH)
  • 101. Nemera
  • 102. Neurotech Pharmaceuticals
  • 103. Nicox
  • 104. Novaer
  • 105. Novaliq
  • 106. Novartis
  • 107. NuMedii
  • 108. Occlugel
  • 109. Ocular Therapeutix
  • 110. Oculex Pharmaceuticals
  • 111. Ocumension Therapeutics
  • 112. Oncimmune
  • 113. OneOncology
  • 114. Opharmic Technology
  • 115. OPHTEC
  • 116. OrbiMed Advisors
  • 117. Orsini Specialty Pharmacy
  • 118. Osage University Partners
  • 119. Paris Diderot University
  • 120. PatientFi
  • 121. Pieris Pharmaceuticals
  • 122. Pixium Vision
  • 123. Polaris Partners
  • 124. PolyActiva
  • 125. PSIMedica
  • 126. Purdue Pharma
  • 127. QLT Plug Delivery
  • 128. Quadra Logic Tech
  • 129. Qura
  • 130. Ramot at Tel Aviv University
  • 131. Ramscor
  • 132. Quadra Logic Technologies
  • 133. Re-Vana Therapeutics
  • 134. Red Cedar Ventures
  • 135. Redwood Pharma
  • 136. Regeneron
  • 137. Relay Therapeutics
  • 138. Ribometrix
  • 139. Ripple Therapeutics
  • 140. Roche
  • 141. Rosalind Advisors
  • 142. Rugen Therapeutics
  • 143. S K Pharmaceuticals
  • 144. Santen Pharmaceutical
  • 145. Second Sight
  • 146. Societa Industria Farmaceutica Italiana (SIFI)
  • 147. Sofinnova Ventures
  • 148. Sparta Systems
  • 149. SpringTime Ventures
  • 150. STADA Arzneimittel
  • 151. Sun Ophthalmics
  • 152. SurModics
  • 153. Sustained Nano Systems
  • 154. SV Life Sciences
  • 155. SWK Holdings Corporation
  • 156. Taiwan Liposome Company
  • 157. TALLC
  • 158. TARGET PharmaSolutions
  • 159. Tempest Therapeutics
  • 160. TerraCycle
  • 161. TPG Capital
  • 162. The French National Centre for Scientific Research
  • 163. Théa Open Innovation
  • 164. TheraKine
  • 165. Tufts University
  • 166. UCL Business
  • 167. University of Arizona
  • 168. University of California
  • 169. University of California
  • 170. University of Cincinnati
  • 171. University of Coimbra
  • 172. University of Colorado Board of Regents
  • 173. University of Illinois
  • 174. University of Maryland
  • 175. University of Michigan
  • 176. University of Northwestern
  • 177. University of Pennsylvania
  • 178. University of Pittsburgh
  • 179. University of the Witwatersrand
  • 180. Versant Ventures
  • 181. ViSci
  • 182. Vision Source
  • 183. Visionex Technologies
  • 184. X Chem
  • 185. Yuuwa Capital